Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Mar;15(3):389.
doi: 10.1007/s11934-013-0389-7.

Lymphotropic nanoparticle-enhanced MRI in prostate cancer: value and therapeutic potential

Affiliations
Review

Lymphotropic nanoparticle-enhanced MRI in prostate cancer: value and therapeutic potential

Ansje S Fortuin et al. Curr Urol Rep. 2014 Mar.

Abstract

Nodal staging in prostate cancer is suboptimal both with respect to current imaging modalities and pelvic lymph node dissection, and thus other techniques are being explored. Lymphotropic nanoparticle-enhanced MRI, also called magnetic resonance lymphography (MRL), is a technique that has shown high sensitivity (65-92 %) and excellent specificity (93-98 %) in detecting prostate cancer lymph node metastases. This technique aids in the detection of metastases in non-enlarged small nodes. MRL has been useful in determining the location and pathways of spread in nodal chains. Knowledge of the location of lymph node involvement is important for decisions regarding appropriate therapeutic options, such as image-guided therapy.. A geographic miss in radiotherapy can be avoided with the use of MRL-guided focal therapy. This paper provides an overview of current literature, lessons learned, and new therapeutic options with nanoparticle-enhanced MRI.

PubMed Disclaimer

References

    1. Eur J Cancer. 2013 May;49(7):1789-90 - PubMed
    1. Int J Radiat Oncol Biol Phys. 2012 Nov 1;84(3):712-8 - PubMed
    1. Clin Radiol. 2008 Apr;63(4):387-95 - PubMed
    1. Prostate. 2009 Mar 1;69(4):352-62 - PubMed
    1. Eur Urol. 2009 Apr;55(4):761-9 - PubMed

LinkOut - more resources